Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Methoxsalen+ECP · 1 trial · 1 indication
The CDAI is a questionaire giving the change of disease acitvity.This study wil llook or a decrease in CDAI score of at least 100.
| Arm | Type | Description |
|---|---|---|
| drug | EXPERIMENTAL | ECP + Uvadex given for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| Methoxsalen +ECP | DRUG | ECP + Uvadex given at weeks 1-12 weeks. |
| Extracorporeal Photopheresis | PROCEDURE | ECP given at weeks 1 through 12. |
Inclusion Criteria: * Signed and dated informed consent must be obtained prior to conducting any study procedure. * Patients must be greater than or equal to 18 years of age. * Patients must have a body weight greater than or equal to 40 kg (88 lb). * Patients must have had Crohn's disease for at l...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
Methoxsalen+ECP is an investigational small molecule being studied for the treatment of Crohn's Disease, a type of inflammatory bowel disease. It is delivered through extracorporeal photoimmune therapy, a procedure where blood is treated outside the body. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Methoxsalen+ECP combines the small molecule methoxsalen with extracorporeal photopheresis (ECP). In this process, blood is collected, treated with methoxsalen, exposed to ultraviolet light, and then returned to the patient. This approach is designed to modulate the immune system's response, which is relevant in autoimmune conditions like Crohn's Disease.
Methoxsalen+ECP is being developed by Icon Plc, a biopharmaceutical company listed on the stock exchange under the ticker symbol ICLR. The company is conducting clinical research on this drug for the treatment of Crohn's Disease.
Methoxsalen+ECP is in Phase 2 clinical development for Crohn's Disease. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The Phase 2 trial has been completed, and the drug remains under investigation for safety and efficacy.
Methoxsalen+ECP has been studied in one clinical trial with the identifier NCT00221026. This Phase 2 trial, titled 'Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease,' enrolled 25 participants and was conducted in the United States, Austria, Belgium, and Germany. The trial has been completed.
Methoxsalen+ECP is associated with the brand name UVADEX, as indicated in the clinical trial title. The trial evaluated extracorporeal photoimmune therapy using UVADEX, which contains methoxsalen. In this context, Methoxsalen+ECP and UVADEX refer to the same treatment approach for Crohn's Disease.